Search Results

Displaying Results 1-6 of 6 "'EQRX'"

Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight

forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-(L)1 inhibitor companies, including FibroGen, EQRx, CStone Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences, Agenus, Tracon Pharmaceuticals, Shanghai Henlius Biotech, Incyte Corporation, and

More news about: DelveInsight Business Research, LLP


Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

the Exon 20 insertion segment. EXKIVITY's withdrawal from this segment stands behind RYBREVANT in the current market. Companies like EQRx International/Hansoh Pharmaceutical, ArriVent BioPharma, Merus/Betta Pharmaceuticals, Cullinan Oncology, and Taiho Oncology are aiming at

More news about: DelveInsight Business Research, LLP


Feb 10, 2026, 17:31 ET PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others.About DelveInsightDelveInsight is a leading Business Consultant and Market Research

More news about: DelveInsight Business Research LLP


Jan 28, 2026, 17:31 ET DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight

well as the market trends, market drivers, market barriers, and key breast cancer companies, including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, and others.About DelveInsightDelveInsight

More news about: DelveInsight Business Research, LLP


Sep 29, 2025, 17:31 ET DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsight

well as the market trends, market drivers, market barriers, and key breast cancer companies, including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, among others. About DelveInsight

More news about: DelveInsight Business Research, LLP


Sep 16, 2025, 17:31 ET KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) | DelveInsight

companies including Pfizer, Novartis, Stemline Therapeutics, Olema Pharmaceuticals, Arvinas, Immutep, AstraZeneca, Roche, Genentech, Evexta Bio, EQRx, Sermonix Pharmaceuticals, Celcuity, Veru Pharma, Evgen Pharma, Eli Lilly, Biotheryx, among others.

More news about: DelveInsight Business Research, LLP


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.